Loading institutional data...
Loading institutional data...
Institutional distribution: ownership decreased -0.59% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -22%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $15.37 today, the market must believe free cash flow compounds 68.2%/yr for a decade (off $508000 normalized FCF).
The market's 68.2% is more optimistic than its 9-yr track record.
2-stage DCF · 0.04B shares · net debt -$54M
mean -90.6% · volatility σ 83% · implied rate exceeded in 0/4 yrs
Central path = implied 68.2%/yr growth; shaded band = ±1σ (83%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $508000 FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $320.2M 100.0% | $292.5M 100.0% | $303.9M 100.0% | $338.8M 100.0% | $316.2M 100.0% | $291.0M 100.0% | $264.2M 100.0% | $270.6M 100.0% | $261.7M 100.0% | $269.8M 100.0% |
| Cost of Revenue | $145.3M 45.4% | $134.8M 46.1% | $149.2M 49.1% | $164.5M 48.6% | $150.5M 47.6% | $134.2M 46.1% | $113.9M 43.1% | $114.6M 42.4% | $117.8M 45.0% | $125.8M 46.6% |
| Cost of Products | — | — | — | — | — | — | — | — | — | $173.5M 64.3% |
| Gross Profit | $174.9M 54.6% | $157.7M 53.9% | $154.7M 50.9% | $174.2M 51.4% | $165.7M 52.4% | $156.8M 53.9% | $150.3M 56.9% | $156.0M 57.6% | $143.9M 55.0% | $143.9M 53.4% |
| Research & Development | $29.4M 9.2% | $26.2M 9.0% | $31.5M 10.4% | $29.9M 8.8% | $30.7M 9.7% | $36.4M 12.5% | $29.7M 11.2% | $28.3M 10.4% | $24.3M 9.3% | $24.1M 9.0% |
| Selling, General & Admin | $43.7M 13.6% | $42.1M 14.4% | $41.2M 13.5% | $40.0M 11.8% | $38.5M 12.2% | $35.9M 12.3% | $37.9M 14.3% | $34.9M 12.9% | $31.0M 11.8% | $31.1M 11.5% |
| Total Operating Expenses | $214.8M 67.1% | $197.7M 67.6% | $401.6M 132.2% | $225.4M 66.5% | $194.2M 61.4% | $192.1M 66.0% | $317.4M 120.1% | $165.4M 61.1% | $158.0M 60.4% | $155.1M 57.5% |
| Operating Income | -$39.9M -12.5% | -$40.0M -13.7% | -$192.4M -63.3% | -$51.2M -15.1% | -$28.5M -9.0% | -$35.3M -12.1% | -$167.1M -63.3% | -$9.4M -3.5% | -$14.2M -5.4% | -$11.2M -4.1% |
| Interest Expense | — | — | -$1.6M -0.5% | $2.7M 0.8% | $688K 0.2% | $861K 0.3% | $907K 0.3% | $5.1M 1.9% | $3.1M 1.2% | $2.8M 1.1% |
| Other Income (Expense), net | $3.9M 1.2% | $4.9M 1.7% | -$817K -0.3% | -$554K -0.2% | -$790K -0.2% | $92K 0.0% | -$130K -0.0% | -$207K -0.1% | -$3.1M -1.2% | -$3.1M -1.2% |
| Pretax Income | -$36.3M -11.3% | -$34.0M -11.6% | -$191.6M -63.1% | -$54.4M -16.1% | -$29.9M -9.5% | -$36.1M -12.4% | -$168.1M -63.6% | -$14.7M -5.4% | -$17.3M -6.6% | -$14.3M -5.3% |
| Income Tax Expense | $442K 0.1% | -$39K -0.0% | -$7.3M -2.4% | -$2.0M -0.6% | -$3.4M -1.1% | -$4.5M -1.5% | -$1.3M -0.5% | -$3.6M -1.3% | -$11.0M -4.2% | -$7.2M -2.7% |
| Net Income | -$36.7M -11.5% | -$34.0M -11.6% | -$184.3M -60.7% | -$52.4M -15.5% | -$26.5M -8.4% | -$31.5M -10.8% | -$166.8M -63.1% | $61.3M 22.7% | $16.3M 6.2% | $5.0M 1.9% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.88 | $-0.83 | $-4.59 | $-1.33 | $-0.68 | $-0.82 | $-4.39 | $1.64 | $0.44 | $0.14 |
| EPS (Diluted) | $-0.88 | $-0.83 | $-4.59 | $-1.33 | $-0.68 | $-0.82 | $-4.39 | $1.64 | $0.44 | $0.14 |
| Weighted Avg Shares (Basic) | 41.5M | 40.9M | 40.2M | 39.5M | 39.0M | 38.3M | 38.0M | 37.5M | 37.1M | 36.6M |
| Weighted Avg Shares (Diluted) | 41.5M | 40.9M | 40.2M | 39.5M | 39.0M | 38.3M | 38.0M | 37.5M | 37.1M | 36.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-17
No standout strengths flagged.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 42.4 | 43.1 | 46.1 | 47.6 | 48.6 | 49.1 | 46.1 | 45.4 |
| Gross Profit | 57.6 | 56.9 | 53.9 | 52.4 | 51.4 | 50.9 | 53.9 | 54.6 |
| R&D | 10.4 | 11.2 | 12.5 | 9.7 | 8.8 | 10.4 | 9.0 | 9.2 |
| SG&A | 12.9 | 14.3 | 12.3 | 12.2 | 11.8 | 13.5 | 14.4 | 13.6 |
| Operating Income | -3.5 | -63.3 | -12.1 | -9.0 | -15.1 | -63.3 | -13.7 | -12.5 |
| Income Tax | -1.3 | -0.5 | -1.5 | -1.1 | -0.6 | -2.4 | -0.0 | 0.1 |
| Net Income | 22.7 | -63.1 | -10.8 | -8.4 | -15.5 | -60.7 | -11.6 | -11.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ANGO: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $54M covers the $8M due within a year 7.2× over. Scheduled principal only (excludes interest & revolver draws). As of 2013-05-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2024 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ANGO | $641M | — | — | 2.0× | 9.5% | 54.6% | -11.5% | -21.5% | -21.5% | — | 140 |
Peers = companies sharing ANGO's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.